Establishing an Optimal Therapeutic Range for Coumarins: Filling in the Gaps

Archives of Internal Medicine

Volumn 164, Issue 6, 2004, Pages 588-590

  O'Donnell, Martin ^a   Hirsh, Jack ^b  

^a Henderson Research Centre ^*

^b HENDERSON RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; COUMARIN ANTICOAGULANT; WARFARIN;

ACUTE HEART INFARCTION; ANTICOAGULATION; BRAIN HEMORRHAGE; CEREBROVASCULAR DISEASE; COMPUTER ASSISTED DRUG THERAPY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; EDITORIAL; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HIGH RISK POPULATION; HUMAN; INTERNATIONAL STANDARD UNIT; OUTCOMES RESEARCH; PRIORITY JOURNAL; STROKE; SUBCLAVIAN VEIN; TREATMENT INDICATION; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; COUMARINS; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; THROMBOEMBOLISM; WARFARIN;

EID: 1642392167     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.6.588     Document Type: Editorial

References (43)

1. Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimum therapeutic range. Chest. 2001;119(suppl): 8S-21S.
2. Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin therapy after cerebral ischemia of presumed arterial origin. Ann Neurol. 1997;42:857-865.
3. Mohr JP, Thompson JLP, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345:1444-1451.
4. Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology. Guidelines for prevention of thromboembolic events in valvular heart disease. Eur Heart J. 1995;16:1320-1330.
5. Stein PD, Alpert JS, Bussey HI, et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest. 2001;119(suppl):220S-227S.
6. Landefeld CS, Rosenblatt MW, Goldman L. Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. Am J Med. 1989;87:153-159.
7. European Atrial Fibrillation Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med. 1995;333:5-10.
8. Cannegieter SC, Rosendaal FR, Wintzen AR, et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med. 1995;333:11-17.
9. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT): Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 1996;348: 423-428.
10. Hylek EM, Skates SJ, Sheehan MA, et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with non-rheumatic atrial fibrillation. N Engl J Med. 1996;335:540-546.
11. Hull R, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982;307:1676-1681.
12. Turpie AGG, Gunstensen J, Hirsh J, et al. Randomized comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet. 1988;1:1242-1245.
13. Saour JN, Sieck JO, Mamo LAR, et al. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med. 1990;322:428-432.
14. Altman R, Rouvier J, Gurfinkel E, et al. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg. 1991;101:427-431.
15. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348:1425-1434.
16. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy to conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349:631-639.
17. Anand SS, Yusef S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA. 1999;282:2058-2067.
18. Segal JB, McNamara RL, Miller MR, et al. Prevention of thromboembolism in atrial fibrillation: a meta-analysis of trials of anticoagulants and antiplatelet drugs. J Gen Intern Med. 2000;15:56-67.
19. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999; 131:492-501.
20. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials [erratum published in Arch Intern Med. 1994;154:2254]. Arch Intern Med. 1994;154:1449-1457.
21. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials [erratum published in Arch Intern Med. 1994;154:2254]. Arch Intern Med. 1994;154:1449-1457.
22. Palareti G, Manotti C, DAngelo A, et al, ISCOAT Study Group (Italian Study on Complications of Oral Anticoagulant Therapy). Thrombotic events during oral anticoagulant treatment: results of the inception-cohort, prospective, collaborative ISCOAT study. Thromb Haemost. 1997;78:1438-1443.
23. Torn M, van der Meer FJM, Rosendaal FR. Lowering the intensity of oral anticoagulant therapy: effects on the risk of hemorrhage and thromboembolism. Arch Intern Med. 2004;164:668-673.
24. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Clinical Epidemiology: A Basic Science for Clinical Medicine. Philadelphia, Pa: Lippincott-Raven Publishers; 1991: 187-302.
25. Bern MM, Lokich JJ, Wallach SR, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. Ann Intern Med. 1990;112:423-428.
26. Fordyce MJF, Baker AS, Staddon GE. Efficacy of fixed minidose warfarin prophylaxis in total hip replacement. BMJ. 1991;303:219-220.
27. Dale C, Gallus A, Wycherley A, Langlois S, Howie D. Prevention of venous thrombosis with minidose warfarin after joint replacement. BMJ. 1991;303:224.
28. Poller L, Thomson JM, MacCallum PK, et al. Minidose warfarin and failure to prevent deep vein thrombosis after joint replacement surgery despite inhibiting the postoperative rise in plasminogen activator inhibitor activity. Clin Appl Thromb Hemost. 1995;1:267-273.
29. Couban S, Goodyear M, Burnell M, et al. A randomized, double-blind, placebo-controlled study of low dose warfarin for the prevention of symptomatic central venous catheter-associated thrombosis in patients with cancer [abstract]. Blood. 2002;100(suppl):703A.
30. Gullov AL, Koefoed BG, Petersen P, et al. Fixed mini-dose warfarin and aspirin alone and in combination versus adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med. 1998;158:1513-1521.
31. Coumadin, Aspirin, Reinfarction Study (CARS) Investigators. Randomized, double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet. 1997;350:389-396.
32. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet. 1989;1:175-178.
33. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505-1511.
34. Connolly S, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol. 1991;18:349-355.
35. Ezekowitz M, Bridgers S, James K, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med. 1992;327:1406-1412.
36. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation. 1991;84:527-539.
37. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255-1262.
38. Adjusted-dose warfarin versus low-intensity, fixed dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet. 1996;348:633-638.
39. van Es RF, Jonker JJC, Verheugt FWA, et al. Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2) Research Group. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet. 2002;360:109-113.
40. Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347:969-974.
41. Fiore L, Ezekowitz MD, Brophy MT, et al, for the Combination Hemotherapy and Mortality Prevention (CHAMP) Study Group. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation. 2002;105:557-563.
42. Medical Research Council. Randomized trial of low intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk: the Medical Research Council's General Practice Research Framework Thrombosis Prevention Trial. Lancet. 1998;351: 233-241.
43. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest. 2001; 119(suppl):22S-38S.